Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Jan Drappatz Clear advanced filters

  • In an arm of an ongoing multicenter phase 2 trial testing different therapies in patients with genetically profiled grade 2 or 3 meningiomas, treatment with an oral CDK4/6 inhibitor met the primary endpoint for progression-free survival at 6 months in patients with CDK or NF2 alterations.

    • Priscilla K. Brastianos
    • Katharine Dooley
    • Evanthia Galanis
    ResearchOpen Access
    Nature Medicine
    Volume: 32, P: 717-724

  • The prognosis for patients with advanced melanoma and CNS metastases is poor. Hodi et al. report the case of a 63-year-old female who was diagnosed with metastatic melanoma from an unknown primary tumor. The authors discuss the use of the human monoclonal antibody against CTLA-4, ipilimumab, in patients with metastatic melanoma.

    • F Stephen Hodi
    • Darryl A Oble
    • Martin Mihm
    Reviews
    Nature Clinical Practice Oncology
    Volume: 5, P: 557-561

  • High-grade gliomas are highly vascularized tumors that represent attractive targets for antiangiogenic therapies. In this article, Norden et al. discuss the rationale for targeting angiogenesis in high-grade gliomas and review the published clinical trial evidence, focusing primarily on therapies that target vascular endothelial growth factor and its receptors.

    • Andrew D. Norden
    • Jan Drappatz
    • Patrick Y. Wen
    Reviews
    Nature Reviews Neurology
    Volume: 5, P: 610-620